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Numerous epidemiologic studies have shown associations between Increased plasma viscosity has been found in association with
exposure to particulate air pollution and acute increases in morbid- elevated sulfur dioxide and particulate levels (7). A recent
ity and mortality, particularly in persons with chronic obstructive study has also shown an association between ultrafine particu-
pulmonary disease. The dosimetry of ultrafine particles in the hu- late exposure and decreased peak expiratory flows in patients
man lung is poorly characterized. We studied the deposition and with asthma (8). Ultrafine aerosol exposure may contribute
clearance of an ultrafine technetium-99m–labeled aerosol in 10 pa- to the increase in morbidity and mortality observed by epide-
tients with chronic obstructive pulmonary disease and in 9 healthy miologic studies.
subjects. Particle retention was followed for 2 hours after inhalation A fair amount of data on the deposition of ultrafine parti-
and again at 24 hours by  scintigraphy. Central-to-peripheral ratios cles in healthy volunteers is available (9–13). However, ul-
indexed airway deposition. Particle accumulation in the liver was trafine deposition data for the diseased lung are limited to
examined by quantifying activity below the right lung. The dose
five chronic obstructive pulmonary disease (COPD) patientsrate for an aerosol exposure of 10 g/m3 was calculated. Patients
and three restrictive lung disease patients studied by Ander-had a significantly greater dose rate than healthy subjects (2.9 
son and colleagues (11). Data for ultrafine particle clearance1.0 versus 1.9  0.4 g/h, p  0.02). Central-to-peripheral ratios
from the human lung are far more limited. Roth and col-were slightly greater in patients than in healthy subjects (1.11 
leagues (14) reported a total lung clearance of 7% over a0.10 versus 1.01  0.11, p  0.05). Clearance did not statistically
24-hour period for an 18-nm (count modal diameter) indiumdiffer between health and disease. On average, 24-hour retention
oxide aerosol in three healthy subjects. To the best of ourwas 85  8% (corrected for isotope dissolution). No accumulation
knowledge, no other ultrafine particle clearance data in hu-in the liver’s vicinity was observed. Data suggest that relative to
mans are reported in the literature.healthy subjects, patients with moderate-to-severe airways obstruc-
tion receive an increased dose from ultrafine particle exposure. A number of studies have been published on the deposi-
tion and/or clearance of agglomeration-mode carbon parti-
Keywords: aerosols; mucociliary clearance; chronic obstructive pulmo- cles, Technegas. The primary particles that compose Tech-
nary disease negas are in the range of 5–20 nm (15, 16). However, before
inhalation, these primary particles coagulate into aggregatesEpidemiologic studies have shown consistent associations be-
with a median diameter in the range of 100 to 160 nm (15–tween the exposure to particulate air pollution and acute
17). Technegas particles can be as large as 225 nm if the timeincreases in morbidity and mortality rates, especially for per-
between aerosol generation and inhalation increases to 8.5sons with obstructive lung and cardiovascular diseases (1, 2).
minutes (16). Although Technegas is frequently referred toSome toxicologic studies have implicated ultrafine particles
as an ultrafine aerosol (18–20), inferences based on these(less than 0.1 m in diameter), which by count constitute
studies with regard to the behavior of ultrafine particles inthe majority of urban particulate air pollution, as having
the respiratory tract should be made with caution.increased toxicity relative to larger particles composed of the
From a dosimetric viewpoint, the distinction between ansame materials (3, 4). Epithelial uptake of ultrafine particles
inhaled aerosol with a median diameter of 20 nm versus onemay occur in as little as 1 hour after exposure and may cause
of 100 or 200 nm is very important. Particle size affects thedamage to epithelial cells, pulmonary edema, and eventually
site and amount of particle deposition as well as subsequentfibrosis (4, 5). An increased probability of death for persons
clearance. Considering a sedentary breathing pattern (tidalwith cardiovascular diseases has been proposed as a result
volume [Vt]  500 ml, frequency [f]  15 min1), the totalof an inflammatory response caused by ultrafine particle over-
deposition of 20-nm particles is 2.7 times greater than pre-loading and subsequently increased blood coagulability (6).
dicted for 100-nm particles and is 4.3 times greater than
predicted for 200-nm particles (21). Moreover, the site of
deposition in the lung shifts proximally with decreasing parti-
cles size below 100 nm (13). This proximal shift in deposition
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Figure 1. The aerosol delivery system. Once the subject began breath-
ing through the pneumotach, a three-way valve was switched to supply
aerosol rather than room air. One-way valves routed aerosol to and
from the subject. Exhaled aerosol was captured on Filter 1, a low-
resistance filter (BB-5OT; Pall Biomedical). The aerosol’s specific activity
and in vitro isotope leaching from particles were based on analysis of
Filter 2, a glass fiber filter (Type A/E; Gelman Sciences, Ann Arbor, MI).
The aerosol’s activity median diameter was determined using a diffusion
battery (25) and a glass fiber filter, Filter 3.
were also determined (22). This study was approved by the
Committee on the Protection of the Rights of Human Sub-
jects (School of Medicine, University of North Carolina at
Chapel Hill, NC). Before participating in this study, all sub-
jects were informed of the study’s associated risks and signed
a statement of informed consent.
METHODS
Figure 2. An initial deposition scan for a COPD patient (61-year-old
female, 31% predicted FEV1) illustrating whole lung, central, and theAerosol Inhalation
liver ROI. The whole-lung ROIs for each lung were set at 20% of theWe have previously described the generation and characterization of
peak xenon equilibrium counts. Central ROIs, with dimensions equalthe experimental technetium-99m–labeled ultrafine carbon aerosol (23).
to half the lung’s width and one-third its height, were positioned onTo control coagulation, aerosol was continuously generated and diluted
the interior boundary of the lung, centered by height. A liver ROI waswith filtered air.
established immediately below the right lung with dimensions of oneThe subjects inhaled aerosol at their natural breathing pattern (24)
third the lung’s height and its full width. Despite severe COPD, qualita-until approximately 25 Ci was deposited in the lung. Activity was
tively, the pattern of deposition appears fairly uniform and quantita-monitored by a single crystal (NaI) scintillation detector (ND detector,
tively, the patient’s C/P0 ratio is still only 1.17.Model LMS-44; Nuclear Data Inc., Smyrna, GA) against the back.
Figure 1 illustrates the aerosol delivery system and sampling locations.
The aerosol’s count median diameter (CMD) was measured by a Scan-
ning Mobility Particle Sizer (TSI Incorporated, St. Paul, MN) for 10
subjects. The aerosol’s activity median diameter (AMD), and leaching
tration of 10 g/m3. This exposure concentration was used becausecharacteristics were determined for all subjects (23, 25).
epidemiologic studies commonly express health risk from ambient par-Before aerosol inhalation, a xenon-133 equilibrium scan was ac-
ticulate exposure in 10 g/m3 increments (2).quired by a large field of view  camera (Elscint Apex 415, Haifa,
Israel) (26). After aerosol inhalation, retention scans (2 minutes per
Scintigraphic Analysisscan) were recorded for 2 hours by the  camera. At approximately 24
hours after inhalation, subjects returned for a 30-minute retention scan. Figure 2 illustrates regions of interest (ROIs). Pulmonary particle reten-
tion was determined from combined counts of the left and right whole-
Data Analysis lung ROIs (background/decay corrected). Twenty-four–hour retention
The deposition fraction (DF) of aerosol in the lung was defined as was “corrected” for isotope dissolution by dividing by one minus the
fraction of activity leached from particles. Central-to-peripheral (C/P)
DF  1 
AEx
AIn
ratios index large airways deposition (27–29) and were determined for
the initial retention scan (C/P0) and 24-hour retention scan (C/P24). C/
where AEx and AIn are exhaled and inhaled activity, respectively. AEx P ratios were computed as the fraction of aerosol deposited in central
was the ND detector measured counts on Filter 1 (Figure 1). The filter regions relative to peripheral regions and normalized to volume using
was centered at 1 foot from the detector face and counts accumulated the same regions with an xenon equilibrium scan (26).
for 30 seconds. This method was also used for diffusion battery stages, Two statistical methods tested differences in clearance rates between
other filters, and isotope leaching measurements. AIn was the product healthy subjects and COPD patients. At 1, 2, and 24 hours after inhala-
of total inspired volume during aerosol inhalation and the aerosol’s
tion, differences were tested using a two-tailed t test. Differences inspecific activity. Total inspired volume was computed as the product
retention curves through 2 hours after inhalation were tested by a linearof average inspiratory flow, aerosol inhalation time, and fraction of
mixed-effects model (30, 31). The logarithm of retention was used inbreathing devoted to inhalation. Aerosol specific activity was the counts
this model fit by S-plus 2000 Professional (MathSoft Inc., Seattle, WA).on Filter 2 (Figure 1) divided by volume sampled through this filter.
Activity in the liver was quantified through 2 hours after inhalationDF data were corrected for a Vt-dependent bias (Appendix). The dose
for comparison with the results of Nemmar and colleagues (20). Liverrate (Drate) for sedentary breathing was calculated for each subject:
ROI counts (background/decay corrected) were normalized by the sum
Drate  DF · Vmin · C of counts (background corrected) in the whole-lung ROIs and liver
ROI from the initial retention scan.where Vmin is minute ventilation and C is an assumed exposure concen-
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Figure 5. Pulmonary par-Figure 3. The particle DF
ticle retention over thein each subject versus pul-
2-hour period immediatelymonary function. The DF
after inhalation in 10in seven bronchitic pa-
COPD patients (closed cir-tients (gray circles) was sig-
cles) and 9 healthy subjectsnificantly (p  0.04)
(open diamonds). Valuesgreater than in the nine
are mean data, and bars re-healthy subjects (open dia-
flect SEs. Note that themonds) and the three em-
ordinate begins at 80%physemic patients (black
retention. Although notcircles) (see Table 2).
statistically significant, the COPD patients tended to have slower clear-
ance than the healthy subjects.
RESULTS
null. No significant correlations were observed between DF andUnless otherwise stated, data provided in the text are mean 
breathing pattern within any group (e.g., bronchitic subjects)SD, and data illustrated in Figures 5 and 6 are mean  SEM.
nor across groups (e.g., combined data for bronchitic and healthyBetween-group differences were tested using Student’s t test
subjects). DF data as a function of forced expiratory volumes(two-tailed) with the exception of the mixed-effects model used
are illustrated in Figure 3. In healthy subjects (n  8), DF wasto test for differences in particle retention. Pearson correlation
significantly correlated with FEF25–75 (r  0.73, p  0.04). Incoefficients were used to determine associations between vari-
the COPD patients (n  10), because of the emphysemic data,ables. The experimental aerosol had an AMD of 61  4 nm and
there was a positive correlation between DF and both percentagea geometric standard deviation (g) of 2.1  0.1. The aerosol’s
predicted FEV1 (r  0.65, p  0.04) and percentage predictedCMD was 33  2 nm with a g of 1.7  0.03. Primary particles
diffusing capacity normalized to lung volume (r  0.80, p that aggregated to form the experimental aerosol had a CMD of
0.005). Significant negative correlations were again observed forapproximately 22 nm (23). There were no statistically significant
the combined dataset (n  15) of the bronchitic group anddifferences in aerosol characteristics between groups. Anthro-
healthy subjects between DF and both FEF25–75 (r  0.77, p pometric and baseline pulmonary function data are given in
0.001) and percentage predicted FEV1 (r  0.65, p  0.009).Table 1. Single-breath nitrogen washout was not conducted on
Across all subjects, DF was not correlated with these variables.one COPD patient because of equipment failure. The COPD
To better elucidate the driving factors affecting DF, a forwardpatients were subdivided into a bronchitic and an emphysemic
stepwise regression was performed for all subjects (n  18),group, with the latter having less than 60% predicted carbon
which included all pulmonary function data in Table 1, aerosolmonoxide diffusing capacity and diffusing capacity normalized
breathing pattern (Table 2), and lung volumes (FRC, RV, TLC,to lung volume. Significant differences between the COPD pa-
FRC/TLC, RV/TLC). In Table 3, the results of this analysistient subgroups were observed for pulmonary function data (Ta-
show that DF increases with the percentage predicted diffusingble 1), DF data (Table 2), and spontaneous breathing patterns
capacity normalized to lung volume (p  0.001) and decreases(Table 2).
with FEF25–75 (p  0.001).Inhaled aerosol deposition (total and regional) and breathing
The Drate of the aerosol (Table 2), assuming an exposurepatterns during the aerosol inhalations are provided in Table 2.
concentration of 10 g/m3, was significantly increased in theThe DF datum for one healthy subject was discarded because
COPD patients (p  0.02) and the bronchitic patients (p of valve leaks. The aerosol DF in the bronchitic patients was
0.002) relative to healthy subjects. The Drate for the emphysemicsignificantly greater than the DF in either the emphysemic pa-
patients was not significantly different from that of the bronchitictients or the healthy subjects. During aerosol inhalations, the
patients. Figure 4 illustrates Drate as a function of percentagebronchitic group had a significantly longer breathing period than
predicted FEV1. For combined dataset (n  15) of the bronchiticboth the emphysemic group and the healthy subjects. These
group and healthy subjects, Drate was correlated with percentagebronchitic patients also breathed aerosol at a Vt that was signifi-
predicted FEV1 (r  0.74, p  0.002) and to a lesser extentcantly greater than the healthy subjects and tended to be greater
with FEF25–75 (r  0.61, p  0.02). Similarly, across all subjectsthan the emphysemic group. The Vt-dependent DF correction
(n  18), Drate was correlated with both percentage predicted(described in the Methods) increased with decreasing Vt; hence,
FEV1 (r  0.64, p  0.004) and FEF25–75 (r  0.48, p the effect of the DF correction should have been to bias the
0.04). A forward stepwise regression was performed to elucidateobserved increase in DF for the bronchitic patients toward the
Figure 4. Drate in each sub-
Figure 6. Pulmonary particle reten-ject versus pulmonary func-
tion by disease status at 24 hours af-tion. Across all subjects (n 
ter inhalation in 10 COPD patients18), Drate and lung function
and 9 healthy subjects. Values arewere significantly correlated
mean data, and bars reflect SEs. The(r  0.64, p  0.004).
hatched area indicates a correctionHealthy subjects  open dia-
for 23  4% isotope leaching frommonds; emphysemic pa-
particles determined by in vitro mea-tients  black circles; bron-
surements.chitic patients  gray
circles.
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TABLE 1. GROUP MEAN AGE AND PULMONARY FUNCTION DATA
COPD Patients
Healthy Subjects All Patients Bronchitic Patients Emphysemic Patients
(3 M, 6 F) (7 M , 3 F) (5 M, 2 F) (2 M, 1 F)
Age, yr 53  11 61  6.9* 60  7.5 64  5.2
FEF25–75, lps 2.82  0.90 0.50  0.23* 0.57  0.24* 0.34  0.02*
FEV1, % predicted 104  16 54  20* 64  13* 31  9.0*†
FEV1/FVC, % 79  3.1 44  13* 50  10* 29  6.4*†
Raw, cm H2O/lps 1.26  0.42 2.52  0.91* 2.16  0.63* 3.36  1.04*†
sRaw, cm H2O s 4.83  1.69 16.8  14.8* 10.3  3.65* 32.0  21.1*†
DLCO, ml CO/min/mm Hg 23  3.7 17  7.0* 20  5.6 9.6  1.8*†
DLCO, % predicted 112  9.1 72  23* 84  13* 43  4.5*†
DLCO/VA, ml CO/min/mm Hg/L 4.47  0.81 3.03  1.12* 3.60  0.68* 1.68  0.56*†
DLCO/VA, % predicted 109  17 78  27* 92  15‡ 44  14*†
N2, %/L 1.85  0.82 8.88  5.26* 5.69  2.60* 15.3  1.5*†
Xe w, min1 1.00  0.21 0.75  0.28* 0.88  0.19 0.42  0.10*†
Definition of abbreviations: COPD  chronic obstructive pulmonary disease; DLCO  carbon monoxide diffusing capacity; DLCO/
VA  diffusing capacity normalized to lung volume; N2  single breath nitrogen washout’s phase III slope; Raw  airway
resistance; sRaw  specific airway resistance; Xew  multibreath xenon washout rate.
* Significantly different from healthy subjects (p  0.05).
† Significantly different from bronchitic subjects (p  0.01).
‡ Marginally significant difference from healthy subjects (p  0.058).
Values are means  SD. Predictive equations for FEV1 are from Knudson and colleagues (32). Predictive equations for DLCO and
DLCO/VA are from Burrows and associates (33).
factors affecting Drate in the same manner as described for DF. clearance curves between the COPD patients and the healthy
subjects. However, a tendency for slower clearance in the COPDIn Table 3, the results of this analysis show that Drate increases
with both Vt (p  0.001) and specific airway resistance (p  patients than healthy subjects could be observed. As illustrated
in Figure 6, there was also an insignificant tendency for greater0.001).
An index of airway deposition, C/P0 ratios were slightly in- 24-hour retention (uncorrected and corrected for isotope leach-
ing from particles) in the COPD patients relative to the healthycreased in the COPD patients relative to the healthy subjects
(COPD, 1.11  0.10; healthy, 1.01  0.11, p  0.05). In COPD subjects. The 24-hour retention, measured at 23  2 hours after
inhalation, was 64  5% in healthy subjects and 67  4% inpatients, but not in healthy subjects, C/P24 ratios were signifi-
cantly lower than C/P0 (p  0.003). The C/P24 ratios do not differ COPD patients (p  NS). Not differing between groups, the in
vitro leaching of isotope from particles in saline was 23  4%significantly between the healthy subjects and COPD subjects.
The C/P0 in COPD patients was the only C/P ratio that was after 23  2 hours in solution. The 24-hour retention after correc-
tion for this leaching was 84  9% in healthy subjects and 87 significantly different from one (p  0.007). C/P ratios were not
correlated with lung function either within or across groups. 8% in COPD patients (p  NS). This leaching correction was
applied only to the 24-hour retention data and not to the 2-hourPulmonary particle retention through 2 hours after inhalation
for the COPD patients and healthy subjects is illustrated in clearance curves.
No accumulation of particles in the liver ROI was observed.Figure 5. Statistically, there was no difference in the 2-hour
TABLE 2. AVERAGE DEPOSITION (AIRWAYS AND TOTAL) AND BREATHING PATTERNS GROUPED
BY DISEASE STATUS
COPD Patients
Healthy Subjects All Patients Bronchitic Patients Emphysemic Patients
(3 M, 6 F) (7 M, 3 F) (5 M, 2 F) (2 M, 1 F)
DF, % 54  9‡ 62  12 67  8* 48  8†
Drate, g/hr 1.88  0.38 2.90  1.02* 2.77  0.48* 3.20  1.94
C/P0 1.01  0.11 1.11  0.10* 1.13  0.10* 1.06  0.11
C/P24 0.92  0.13 1.00  0.13§ 1.04  0.10§ 0.90  0.14
VT, ml 391  92 621  322 657  333* 537  344
Tinsp, s 2.02  0.24 2.34  0.87 2.73  0.74* 1.44  0.17*†
Vmin, L/min 5.83  1.36 8.13  3.74 6.93  1.65 10.9  6.2*
Definition of abbreviations: COPD  chronic obstructive pulmonary disease; C/P0 and C/P24  central-to-peripheral ratio initially
and at 24 hours, respectively; DF  particle deposition fraction in the lung; Drate  deposition rate a constant 10 g/m3 exposure
to the experimental aerosol; Tinsp  average inspiratory time during aerosol inhalation; Vmin  minute ventilation; VT  tidal volume
during aerosol inhalation.
* Significantly different from healthy subjects (p 	 0.05).
† Significantly different from bronchitic subjects (p  0.02).
‡ DF datum not available for one healthy male subject.
§ Significantly different from C/P0 by paired t test (p  0.03).
Values are means  SD.
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TABLE 3. BEST REGRESSION MODELS FOR PARTICLE with six breathing patterns and a CMD of 40, 60, 80, and 100
DEPOSITION FRACTION IN THE LUNG AND DEPOSITION nm. For the breathing pattern of Vt  500 ml and f  15 min1
RATE IN ALL SUBJECTS (the most comparable to that of our healthy subjects) and a
CMD of 40, 60, 80, and 100 nm, they found the DF of 44  7%,Dependent Variable Independent Variable Coefficient p Value
35  5%, 30  5%, and 26  4%, respectively. Schiller and
DF, % FEF25–75, lps 7.54 0.0003 colleagues (10) also provided a large dataset for a range ofDLCO/VA, % predicted 30.9 0.0012
particle sizes (5 to 200 nm) and 11 different breathing patterns,Constant, % 40.6  0.0001
but only in 4 healthy male subjects. These investigators found(Overall regression, R2  0.62, p  0.0007)
Drate, g/hr VT, L 1.770 0.0008 slightly lower DF than observed in male subjects by Jaques and
sRaw, cm H2O s 0.044 0.0002 Kim (12). For polydisperse carbon particle aggregates (CMD 
Constant, g/hr 1.015 0.0005 26 nm, g  2.3), Frampton and colleagues (35) reported a DF(Overall regression, R2  0.81, p  0.0001) of 66  12% by count and 58  14% by mass in 12 healthy
young adults (6 females and 6 males) spontaneously breathingDefinition of abbreviations: DF  particle deposition fraction in the lung; Drate 
deposition rate a constant 10 g/m3 exposure to the experimental aerosol; DLCO/ on a mouthpiece. As a technical note, the DF data reported by
VA  diffusing capacity normalized to lung volume, predictive equations Burrows Jaques and Kim (12) and by Schiller and associates (10) were
and colleagues (33); sRaw  specific airway resistance; VT  tidal volume during for specific monodisperse particle sizes, as such there should be
aerosol inhalation. no differences in DF determined by count versus mass. Our DF
data are for a polydisperse aerosol and are based on the amount
of radioaerosol collected on filters making them similar to a DF
determined by a change in mass. Although in the range of otherThe fraction of activity in the liver ROI was analyzed at 10-
studies, our methods and results are most similar to that ofminute increments throughout the 2-hour period after inhala-
Frampton and colleagues (35), with a DF of 54  9% for ation. On average across all subjects, the fraction of activity in
polydisperse aerosol (CMD, 33 nm; g  1.7) inhaled with athe liver ROI was 1.3  1.2% initially, 1.4  0.8% at 1 hour, and
Vt  391 ml and f  15 min1 by nine healthy subjects.1.3  0.8% at 2 hours after inhalation. No significant deviation in
Only one prior study’s data are available for comparison ofthe fraction of activity in the liver ROI during the 2-hour period
DF results in patients. For the CMD of 20, 40, and 60 nm respiredwas observed in COPD patients, healthy subjects, nor across all
at Vt  1000 ml and f  12 min1, Anderson and colleaguessubjects. There was no significant difference in the fraction of
(11) reported the DF (respective to CMD) of 47  9%, 38 activity in the liver ROI between the COPD patients and healthy
6%, 33  9% in 10 healthy subjects and 54  4%, 46  4%,subjects.
45  4% in 5 patients with obstructive lung disease. These DF
data are lower than we have observed. Anderson and colleagues’
DISCUSSION DF data for healthy subjects are also lower than reported by
Jaques and Kim (12) and Schiller and colleagues (10). However,We investigated the deposition and clearance of an ultrafine
Anderson and colleagues’ relative increases in DF due to ob-aerosol (CMD, 33  2 nm; AMD, 61  4 nm) in a group of 10
structive lung disease are 15, 21, and 36% for the respectiveCOPD patients (45–70 years old) with moderate to severe air-
CMD of 20, 40, and 80 nm. Similarly, for our 33-nm CMDways obstruction and 9 healthy volunteers (40–67 years old).
aerosol, we found DF increased by 15% in COPD as a wholeWe found no difference in particle clearance rates between the
and by 26% in the bronchitic patients relative to the healthyhealthy subjects and COPD patients, nor were we able to detect
subjects. Anderson and colleagues (11) also reported that DFthe accumulation of particles in the vicinity of the liver. Based
was not correlated with any spirometric or lung volume parame-on diffusing capacity, the COPD patients were subdivided into
ters in the five obstructive lung disease patients. Possibly duegroups of seven bronchitic patients and three emphysemic pa-
to our larger sample size, we found correlations between lungtients. We found an increased particle DF in the bronchitic
function and DF in the COPD patients.patients relative to the healthy subjects and emphysemic patients
Unlike most prior studies of particle deposition, the subjects(Table 2); however, when deposition was expressed as a Drate, it
in our study respired aerosol at their natural sedentary breathingwas observed that the Drate in emphysemic patients actually
pattern, whereas other studies typically have all subjects breathetended to be increased relative to the bronchitic patients. More-
at the same fixed conditions. Although this disparity in methodover, larger relative increases in Drate (54%) were observed than
complicates comparisons between subject groups and betweenfor DF (15%) in the COPD patients compared with healthy
studies, it is advantageous in that data may be derived that aresubjects. This is due to the fact that, at rest, the COPD patients
applicable to real-world exposure-dose scenarios. Accordingly,breathe spontaneously with a higher minute ventilation than the
Drate were calculated and provide an estimate of the ultrafinehealthy individuals (24).
particle mass that would be deposited per hour in the lungs ofA comparison of our results with prior studies is possible for
subjects while at rest. We found that the COPD patients had athe DF data in healthy subjects, and to a lesser extent, in the
54% greater Drate than did healthy subjects (p  0.02). BasedCOPD patients. However, even comparisons of DF in healthy
on DF alone, these patients had an increase of only 15% relativeindividuals are complicated because of differing methods. For
to healthy subjects (p  NS). Interestingly, the emphysemicexample, decreasing particle size below 100 nm and increasing
patients appeared to have 11% less deposition than the healthyresidence time will effect an increase in DF (9, 10, 12, 13).
subjects based on their average DF, whereas their Drate showedTheoretically, there is also an effect of polydisperse versus mono-
a 70% average increase in deposition relative to the healthydisperse aerosol inhalation on DF, such that increasing polydis-
subjects. Again, this is due to the fact that, at rest, these patientspersity below approximately 40 nm should decrease DF, whereas
tended to breathe spontaneously with a higher minute ventila-above this particle size, it should cause an increase in DF (34).
tion than the healthy individuals. These findings are consistentFinally, age effects on ultrafine particle deposition are unknown.
with Bennett and colleagues (24), who found greater increasesWith these issues noted, the data of a few studies are discussed
in the Drate than for the DF in COPD patients relative to healthylater here.
subjects for a fine 2-m mass median aerodynamic diameterJaques and Kim (12) conducted an extensive particle deposi-
tion study in 22 young healthy adults (11 females and 11 males) aerosol.
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Particle deposition within the airways was also increased in turn affect regional particle deposition. Ultrafine particles may
penetrate into poorly ventilated regions and then have enhancedCOPD patients relative to the healthy subjects. An index of
excess airways deposition, C/P0 ratios were significantly (p  deposition due to the long time constant of these regions. In-
creased particle deposition in poorly ventilated lung regions has0.05) increased in the COPD patients relative to healthy subjects
(1.11  0.10 versus 1.01  0.11). The increased C/P0 ratios in been reported for aerosols in the 0.5 to 1.0 m size range and
attributed to increased residence time in obstructed areas (42,COPD patients could reflect enhanced airways deposition of
ultrafine particles by turbulent diffusion caused by airway ob- 43). On the other hand, as ventilation is reduced to obstructed
regions, healthier regions receive the balance of ventilation andstruction, although no significant correlations were observed be-
tween C/P0 ratios and spirometry to support this supposition. In associated particle exposure. To an extent, these phenomena
have been observed in patients with mild-to-moderate asthmaaddition to their increased Drate, the increased C/P0 ratios show
the potential for greater particle doses to the airways of patients where large wedge-shaped regions of the lung were observed
absent the deposition of fine particles (approximately 0.12 mrelative to healthy individuals. It should be noted, however, that
the “increased” C/P0 ratios that we observed in COPD patients diameter) (44). Whether ultrafine particle deposition is enhanced
in poorly ventilated regions or shifted to healthy regions, thereflect far less airways deposition than is found for coarse parti-
cles, which deposit by inertial impaction. For example, Bennett pattern of deposition is in all likelihood far less uniform in COPD
patients than in the healthy subjects. As a first approximationand Zeman (36) found a C/P0 of 2.2 in 12 COPD patients (FEV1/
FVC  55%) who respired a 5-m mass median aerodynamic of this effect, Miller and colleagues (45) assumed that a quarter
of the parenchymal lung in COPD patients might receive all thediameter aerosol at Vt  500 ml and f  30 min1. At 24
hours after inhalation, those patients had a mean retention of deposition normally distributed across the full parenchymal lung.
Applying this approximation and the observed Drate, the paren-approximately 13%, suggesting that 87% of the particles were
deposited within and subsequently removed from the airways chymal lung tissues in COPD patients would receive a 600%
greater dose than these tissues within a healthy individual. Suchvia mucociliary clearance. Quite the opposite, we found a 24-
hour retention of 87  8% in COPD patients after correction an increased surface dose in sensitive patients might be sufficient
to elicit an inflammatory response with systemic effects such asof isotope leaching. Despite the statistically increased C/P0 ratios
in our COPD patients, comparison with the data for larger parti- those proposed by Seaton and colleagues (6).
Others have proposed that ultrafine particles elicit an effectcles illustrates the small degree of ultrafine particle deposition
in the bronchial airways. by moving rapidly (within minutes after deposition) into circula-
tion and accumulating in other organs such as the liver. WePulmonary particle clearance was similar between the COPD
patients and healthy subjects. There was an insignificant ten- found no such accumulation of particles in the vicinity of the
liver. On average across all subjects (n  19), we observed 1.3 dency for greater retention in the COPD patients relative to the
healthy subjects during the 2-hour period after deposition, which 1.2% of the deposited activity in the liver ROI on the initial
retention scan. This activity may be due to scatter from the lungwas also observed at 24 hours. Retention at 24 hours after deposi-
tion was corrected for 23% isotope leaching from particles in and/or overlap of lung parenchyma in the liver ROI. The relative
amount of activity in the liver ROI did not significantly deviatesaline. The leaching characteristics of the isotope did not differ
between the healthy subjects and COPD patients. On average, over the 2-hour period after inhalation. In contrast, Nemmar
and colleagues (20) reported that 8% (n  5) of depositedthis leaching correction increased 24-hour retention from 66 
5% to 85  8%. This in vitro method has been used by others activity accumulated in the liver by 5 minutes after inhalation.
They also observed the accumulation of 25% of the depositedand provides a conservative estimate of leaching, that is, greater
technetium-99m dissolution from particles, relative to in vitro activity in the bladder by 45 minutes with large unquantified
amounts of activity in the thyroid, salivary glands, and stomach.leaching in simulated lung fluid (37) or in vivo leaching after
radiolabeled aerosol inhalation (38). Hence, 85  8% is likely Although not reported, their pulmonary retention at 45 minutes
after inhalation must be on average less than 67% after account-an upper bound for the expected particle retention at 24 hours
after deposition. It is not expected that isotope leaching would ing for activity in the liver and bladder. This contrasts sharply
with the 91% average retention that we observed at 45 minutes.have caused differences between the healthy subjects and COPD
patients. Smokers have been shown to have increased lung epi- Prior studies have reported pulmonary retention at 45 minutes
for Technegas, the aerosol used by Nemmar and associates (20).thelial permeability as demonstrated by increased clearance rates
of inhaled soluble compounds (39). Hence, an effect of leaching In contrast to Nemmar and colleagues (20), the Technegas pul-
monary retention reported by Roth and associates (17) was 95%might have been to increase rapid (less than 20 minutes) clear-
ance in the COPD patients relative to the healthy subjects. Refer- (n  3) and by Isawa and colleagues (46) was 98% (n  11).
The disparity in results between Nemmar and colleagues (20)ring to Figure 5, clearance rates were indistinguishable until 30
minutes after inhalation. The pulmonary clearance kinetics of and the results of our present study and prior studies using
Technegas may be due to Pertechnegas contamination. Unlikethe experimental aerosol appear quite similar for the COPD
patients and healthy subjects. Technegas, which is considered relatively stable in the lung,
Pertechnegas is thought to be rapidly ionized to pertechnetateBased on similar clearance kinetics and only modestly in-
creased C/P0 ratios, relative to healthy subjects, it is likely that (TcO4 ) in the presence of moisture (39, 47, 48). In fact, the
pulmonary clearance kinetics of inhaled pertechnetate and Per-the increased Drate in COPD patients primarily affects the paren-
chymal lung. Assuming a uniform ventilation distribution in the technegas are statistically indistinguishable (39, 47). Technegas
and Pertechnegas are produced by the same proprietary genera-lung, the parenchymal surface dose in COPD patients is 54%
greater than in healthy subjects. However, in COPD patients, tor under differing atmospheres (Technegas, 100% argon; Per-
technegas, 3% oxygen and 97% argon) (16, 39, 47, 49). Thethe assumption of uniform ventilation is questionable. In patients
with COPD, the time constants of some diseased regions are transition from Technegas to Pertechnegas occurs abruptly at
an oxygen concentration of between 0.1% and 0.2% (49). Hence,thought to be in excess of 3 seconds, whereas healthy regions
might be expected to have a time constant of the order of 0.1 minimal oxygen contamination within the generator can cause
Pertechnegas contamination of Technegas. Even when producedseconds (40). This variability in regional time constants leads to
the observation of slower and less uniform rates of air exchange under a 100% argon atmosphere, Technegas still has an immedi-
ately soluble fraction of approximately 20% (49). Xu and col-in patients relative to healthy individuals (41), which may in
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